THERAMetrics holding AG (SIX: TMX) announces its financial results for the quarter ended March 31, 2015 and its Board appointments for 2015. Freitag, 15. Mai 2015 - 19:53

Stans, Switzerland, May 15, 2015

THERAMetrics holding AG (the “Company”) published yesterday its consolidated financial results for the quarter ended March 31, 2015.

For the quarter ended March 31, 2015 the Company generated revenues of EUR 4 million and EBITDA of negative EUR 1.2 million.

By comparison, for the quarter ended March 31, 2014, the Company generated revenues of EUR 3 million and EBITDA of negative EUR 1.7 million.

Raffaele Petrone, Chairman and CEO of the THERAMetrics, comments: “Although revenues are higher quarter over quarter, this is the result of unusually high pass-through revenue. Growth of our CRO service revenue remains a fundamental focus and challenge of the Company. The positive development to take from the first quarter 2015 is that EBITDA has improved by EUR 500,000 which shows that our restructuring efforts are finally having the financial impact we expected.”

Mr. Petrone adds: “Our increased efforts in business development are starting to pay off this year, with a notable increase in the pipeline of the CRO business as well as steadily increasing success in the Discovery business via the DRR2.0 platform and the licensing out of Medical Product Candidates (MPCs).”

Following the Company’s annual shareholders’ meeting earlier in the week, where Mr. Fulvio Citaredo was elected to the Board of Directors, the Company today also announces the following board-level appointments: Mr. Michael Keller has been re-appointed Vice Chairman of the Board of Directors, Mr. Robert Patterson has been re-appointed Chairman of the Nomination & Compensation Committee, Mr. Citaredo has been appointed to the Audit & Finance Committee and Mr. Claudio Palladini has been appointed Chairman of the Audit & Finance Committee.

About Therametrics holding AG
Therametrics holding AG is a global tech-based Contract Research & Development Organisation dedicated to providing a full range of technological solutions through the entire value chain of drug discovery and development. The company is listed on the SIX Swiss Exchange under the symbol TMX and is headquartered in Stans, Switzerland.

For further information please contact
Raffaele Petrone
THERAMetrics holding AG
Investor and External Relations
T. +41 (0)44 723 59 59
F. +41 (0)44 726 90 12
investor@therametrics.com
www.therametrics.com

Media relation:
Press Area - Società & Servizi srl
mi@areacomunicazione.info

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Files:

pdf eng